Company / Operating Cash Flow
Gain Therapeutics, Inc. Operating Cash Flow History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$18.9M
FY2024
5-year range
-$18.9M / -$3.2M
FY2021-FY2024
Trend
-28.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$3M in FY2021 to -$19M in FY2024.
Based on SEC 10-K filings.
-$19M in FY2024.
Declined from -$12M to -$19M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2024, operating cash flow decreased 28.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$18.9M | -28.4% |
| FY2023 | -$14.7M | -18.8% |
| FY2022 | -$12.4M | -281.6% |
| FY2021 | -$3.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026